SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung Cancer
Status:
Terminated
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
The present trial will be performed to evaluate whether SHR1020 in combination with docetaxel
in patients with Local Advanced or Metastatic or recurrent Non Squamous NSCLC is more
effective as compared to placebo in combination with docetaxel. A secondary aim is to obtain
safety information as well as information on quality of life of patients treated with SHR1020
in combination with docetaxel.